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Summary The investigative anti-tumour agent 5,6-dimethylxanthenonone-4-acetic acid (DMXAA, NSC 640488), developed in this laboratory
as an improved analogue of flavone acetic acid (FAA, NSC 347512), is currently in clinical trial. The ability of DMXAA to up-regulate tumour
necrosis factor (TNF) mRNA and protein synthesis in cultured human peripheral blood leucocytes (HPBLs) has been investigated and
compared with that of flavone acetic acid (FAA) and of bacterial lipopolysaccharide (LPS). Human peripheral blood leucocytes were isolated
from buffy coats obtained from a blood transfusion centre and also from blood samples from laboratory volunteers. At a concentration of
400 gg ml-' and an incubation time of 2 h, DMXAA up-regulated mRNA synthesis in six of eight individuals tested, as measured by Northern
blotting. The degree of up-regulation varied in different individuals from one to nine times that of control levels. In contrast, FAA caused no
induction above that of control levels and in some cases suppressed expression relative to controls, extending previous data that DMXAA but
not FAA up-regulates TNF mRNA in the human HL-60 tumour cell line. At the same concentration but with longer incubation times (6-12 h),
DMXAA induced increases in TNF protein in 11 of 15 samples of HPBLs from buffy coats and also in 11 of 15 samples of HPBLs from
volunteers, as measured by cytotoxicity assays with L929 cells. FAA caused no increase in TNF protein, while LPS induced TNF to
approximately 20-fold higher levels than did DMXAA. Considerable heterogeneity of response was observed with both sources of HPBLs, and
there was little or no correlation between the extent of TNF induction by DMXAA and LPS in individual samples. In vitro analysis of the
response of human peripheral blood leucocytes to DMXAA may be a useful test in clinical trials of agents such as DMXAA.
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DMXAA (5,6-dimethylxanthenone-4-acetic acid; NSC 640488), a
novel biological response modifier, was developed in this labora-
tory as an improved analogue of FAA (flavone acetic acid)
(Rewcastle et al, 1991). While FAA shows excellent activity
against a range of murine solid tumours (Plowman et al, 1986;
O'Dwyer et al, 1987), it has no clinical activity as a single agent
(Kerrand Kaye, 1989). FAA and DMXAA have little direct in vitro
cytotoxicity and appear to mediate their anti-tumour activity
through host immune modulation (Ching and Baguley, 1987;
Finlay et al, 1988; Baguley et al, 1989). DMXAA is 12 times more
dose potent than FAA in its immune-stimulating effects and anti-
tumour activity in mice (Rewcastle et al, 1991; Philpottet al, 1995).
However, the key question with this class of agents is whether
DMXAA can act more efficiently than FAA against human cells.
TNF (tumour necrosis factor-a) appears to play a pivotal role in
the anti-tumour effects of DMXAA and FAA in mice. Among
analogues of DMXAA tested, a strong correlation was observed
between elevation ofserum TNF activity and anti-tumour potential
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(Philpott et al, 1995). Scheduling ofDMXAA in two doses given 3
days apart led to a ninefold increase in serum TNF production and
an improved anti-tumoureffectcompared with that obtained with a
single dose (Philpott et al, 1995). Antibodies to TNF inhibit FAA-
induced tumour vascular collapse (Mahadevan et al, 1990) and
reduce its anti-tumour effect (Pratesi et al, 1990). These observa-
tions suggest that TNF induction could be a useful indicator ofthe
activity by this class ofagents.
FAA is an efficient inducer of mRNA for IFN (interferon) and
TNF, both in vivo and in cultured murine splenocytes and periph-
eral blood leucocytes. Although it also induces IFN secretion in
cultured mouse lymphocytes, it does not up-regulate cytokine
gene expression or protein secretion in cultured human peripheral
blood leucocytes (HPBLs) (Futami etal, 1991). DMXAA up-regu-
lates TNF mRNA in the human HL-60 and in murine J774 cells,
while FAA induces TNF mRNA in J774 cells only (Ching et al,
1994). These observations suggest that an activation pathway is
present in both human and murine cell systems but that only
DMXAA is able to stimulate the pathway efficiently in human
cells. In this report, we have extended our previous studies to
examine the production of TNF in cultures of HPBLs in response
to DMXAA and FAA. We have also compared responses to these
agents with that to LPS (lipopolysaccharide, endotoxin), a clas-
sical inducer ofTNF synthesis (Carswell et al, 1975).
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Figure 1 Induction of TNF mRNA by DMXAA or FAA in HPBLs in two responders. (A) Northern blots probed for TNF mRNA induced after in vitro exposure
to DMXAA or FAA for 2 h. Lane 1, unstimulated controls; lane 2, DMXAA (200 jig kg-'); lane 3, DMXAA (400 jg kg-'); lane 4, FAA (200 jg kg-'); lane 5, FAA
(400 ig kg-'). (B) Relative intensity of signals was determined by scanning densitometry. (C) 28S and 18S ribosomal RNA bands stained with ethidium bromide
MATERIALS AND METHODS amount of 5% sodium bicarbonate and diluted in culture medium.
Materials
DMXAA (sodium salt), synthesized in this laboratory by Dr GW
Rewcastle and others (Rewcastle et al, 1991), was dissolved in
The culture medium was o-minimal essential medium (Gibco, culture medium. Solutions were prepared freshly for each experi-
Grand Island, NY, USA) supplemented with 10% fetal calf serum, ment and protected from light (Rewcastle et al, 1990). LPS (E. coli
Gibco NZ, 100 units ml- penicillin and 100 ,ug ml streptomycin serotype 0127:B8; Sigma, St Louis, MO, USA) was dissolved in
sulphate. FAA (free acid) was kindly provided by the National culture medium. Solutions were filter sterilized before addition
Cancer Institute, Bethesda, MD, USA, dissolved in a minimal to culture.
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Figure 2 Induction of mRNA in HPBLs by DMXAA and FAA. HPBLs from
eight individuals were cultured with DMXAA or FAA (400 9g ml-') and tested
for TNF mRNA using Northern blot analysis. Relative amounts of mRNA
produced, as assessed by scanning densitometry of the blots, were
expressed as a ratio of the levels detected in the untreated control samples.
C], FAA; 1, DMXAA
Human peripheral blood leucocytes (HPBLs)
Approval forthe use ofHPBLs in this project was obtained from the
North Health Ethics Committee, Auckland, New Zealand. Partly
purified buffy coats fromhealthy donors (identified by sex and age),
which had been stored in CPD buffer (0.1 M sodium citrate, 0.015 M
monosodium phosphate, 0.071 M dextrose; BaxterPharmaceuticals,
Auckland, New Zealand) as an anticoagulant, were purchased from
the regional blood transfusion centre. They were diluted threefold
with a-minimal essential medium before use. Whole blood was
also taken from healthy volunteers in the laboratory. HPBLs were
isolated from the above sources by fractionation on Ficoll-Paque
(Pharmacia, Uppsala, Sweden) gradients and cultured overnight at
107 cells ml-' at 37°C in an atmosphere of5% carbon dioxide in air.
FAA, DMXAA or LPS were then added to culture and, after further
incubation for various times, the supernatants were harvested for
TNF determination. In some experiments, Trizol (Gibco BRL, Life
Technologies, Gaithersburg, MD, USA) was added to the cells after
the supernatant had been removed, and mRNA was extracted
according to manufacturer's instructions.
TNF assay
L929 cells (3x104 in 100 ,l ofculture medium) were placed in each
well of flat-bottomed 96-well plates and allowed to adhere
overnight. Actinomycin D (Merck, Sharpe and Dohme, Granville,
NSW, Australia) was added to 16gg ml' (i.e. to provide a final
concentration of5.3 jig ml-'). Samples were addedto thefirstrowof
wells to give a total volume of300gl and sequential threefold dilu-
tions of the sample were then performed over the length of the
plates. Plates were then incubated for 24 h at 370C, MTT [3-
(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide;
500 jg ml-'] was added and the cultures were incubated for 1 h to
allow dark-blue crystals to appear. Supernatants were removed and
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Figure 3 Time course of TNF secretion in response to DMXAA. HPBLs
from nine individuals (age and sex as indicated) were cultured with DMXAA
8 (400 9g ml-'). The culture supernatants were harvested at different times and
were assayed for TNF activity; mean values were plotted. Vertical lines
represent standard errors of the mean
100 ,ul ofdimethyl sulphoxide (Prolabo, Paris, France) was added to
solubilize the crystals. Absorbance at 570 nm was measured using
an automatic ELISA reader (MR 600, Dynatech, Alexandria, VA,
USA). Dose-response curves were constructed, and the dilutions
that gave a 50% reduction in staining intensity were determined
(Philpott et al, 1995). One unit ofTNF was defined by this assay as
the amountreducing staining intensity ofL929 cells by 50%.
Northern blot analysis of mRNA
Total cellular RNA was isolated using eitherTrizol or a single-step
acid-phenol-chloroform extraction procedure as previously
described (Chomczynski and Sacchi, 1987). RNA was applied
(15 jig per lane) and was separated by denaturing gel electro-
phoresis on a 1% agarose-17% formaldehyde gel. RNA was then
transferred to a nylon membrane (Hybond N+) by capillary action
using 20 x SSC (SSC: 0.15 M sodium chloride, 0.015 M sodium
citrate), and the RNA was then UV cross-linked and baked on to
the membrane. Prehybridization (1 h) and hybridization (over-
night) were carried out at 420C in 50% formamide, 0.075 M
sodium chloride, 0.05 M sodium dihydrogen phosphate, 5 mM
EDTA, 0.001% (w/v) polyvinyl pyrrolidone, 0.001% (w/v) bovine
serum albumin (Sigma, A-4503), 0.001% (w/v) Ficoll (Sigma, F-
4375), 0.01 mg ml-' herring sperm DNA and 0.5% sodium
dodecyl sulphate (SDS). An 820 basepair cDNA sequence
(Genentech, San Francisco, CA, USA) that encodes for the human
TNF protein was labelled with 32p using dCTP (3000 Ci mmol-',
NEN, Boston, MA, USA) and arandom-primed DNA labelling kit
(Boehringer Mannheim, Germany). Labelled probe was separated
from free radiolabelled nucleotide by centrifugation through a G-
25 Sephadex column and was added to the hybridization buffer to
106 c.p.m. ml-'. After hybridization, filters were washed in 2 x
SSC and 0.1% SDS for 30 min at 68°C and in 1 x SSC and 0.1%
SDS for 20 min at 68'C. The filters were blotted dry and exposed
to radiographic film (Kodak XAR-5) at -700C with intensifying
screens for 10 days. The mRNA signal was quantitated by laser
densitometric scanning. Loading of the 28S and 18S RNA bands
in different lanes was visualized under ultraviolet light after
staining with ethidium bromide.
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Figure 4 Production of TNF in cultures in response to DMXAA, FAA and
LPS. HPBLs (107 ml-') from 15 individuals (sex and age of each as shown)
were cultured with DMXAA (400 9g ml-'), FAA (400 9g ml-'), LPS (5 9g ml-')
or without any stimulation (controls). Supernatants were harvested after 6 h
and were assayed for TNF activity. TNF units were defined using the L929
assay
RESULTS
Induction of TNF mRNA in HPBLs
HPBLs from eight blood donors were exposed for 2 h to DMXAA
or FAA at 200 and 400 jg ml-' with exposure time and drug
concentrations based on optimal conditions in previous studies
with myeloid cell lines (Ching et al, 1994). Cellular mRNA was
extracted and assayed for TNF mRNA. Greater induction was
obtained at 400 jg ml' for HPBLs (Figure 1). The amounts of
TNF mRNA obtained in the HPBLs from the eight individuals in
response to DMXAA and FAA (400 jig ml-') were compared as
ratios with the amount ofTNF mRNA in untreated control cultures
for each individual (Figure 2). Induction of TNF mRNA was
obtained in six ofthe donors in response to DMXAA, with two of
these donors showing an almost tenfold increase over control
levels. In contrast, TNF mRNA levels greater than those of
controls were not observed in any of the donors in response to
FAA, and in half ofthe donors levels were lower than in unstimu-
lated cultures.
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Figure 5 TNF production by HPBLs in response to different concentrations
of DMXAA. HPBLs were cultured with different concentrations of DMXAA for
8 h (donors T, U and V) and for 12 h (donors A2, C2 and D2), after which the
supernatant was collected and assayed for TNF
TNF production in cultures of HPBLs
HPBLs from nine blood donors (107 per culture) were incubated
for various times with DMXAA (400,g ml-') and the culture
supernatants were assayed for TNF activity. Secreted TNF began
accumulating in the culture supernatant after 4 h and increased up
to 12 h, with the same trend observed for each of the donors
(Figure 3). In another experiment, TNF activity was measured 8,
24, 48 and 72 h after exposure to DMXAA and, in all cases, the
levels found at 24 and 48 h were lower than those expressed at 8 h.
A 6-h time point was chosen for studies on the heterogeneity of
the response. HPBLs from 15 donors (eight female, seven male,
ages from 16 to 65 years) were incubated with DMXAA
(400 jig ml-'), FAA (400 jg ml-') or LPS (5 jig ml-). Supernatants
from HPBL cultures in 11 of these donors demonstrated TNF
activity above background after stimulation with DMXAA (Figure
4). In contrast, production ofTNF in HPBLs cultured with FAA was
not above the background ofunstimulated cells and, in experiments
in which background TNF production in unstimulated cultures was
measurable, FAA inhibited this background production. The levels
of TNF obtained in response to DMXAA (517 + 91 units per
107 cells) were lower than those obtained in response to LPS
(11 900 ± 2500 units per 107 cells). The responses to both DMXAA
and LPS were variable among individual donors, were only weakly
correlated to each other (r = 0.56; P < 0.05) and did not correlate to
background levels. In particular, two high responders to DMXAA
(donors N and 0) were not responsive to LPS.
We also examined the dose-response of HPBLs to DMXAA,
measuring TNF activity after 8 h for blood donors T, U and V, and
after 12 h for blood donors A2, C2 and D2 (Figure 5). Although
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Figure 6 Heterogeneity of response to DMXAA of freshly prepared HPBLs.
Blood samples from eight volunteers (age and sex as indicated) were taken
on four different occasions at approximately 3-weekly intervals and HPBLs
were cultured with DMXAA (400 ,g ml-'). Supernatants were harvested after
12 h and tested for TNF activity. Bars represent the mean of determinations
for each of the individuals, and vertical lines represent standard errors of the
mean
TNF production tended to increase with increasing concentrations
of DMXAA, one of the donors (D2) gave a higher response at
400 ugml- than at 800jg ml.
TNF production in cultures of HPBLs from fresh blood
samples
All previous experiments were carried out using HPBLs isolated
from blood donors. In order to rule out the possibility that the inter-
individual variability in the responses was due to the variation in
the storage time or condition of the purchased buffy coats, we
carried out experiments with HPBLs from fresh blood from
volunteers within the laboratory. Samples from 15 individuals were
tested (five female and ten male, ages 20-54 years). In this experi-
ment, blood was collected into heparinized tubes rather than in
CPD buffer as an anticoagulant (an initial experiment with blood
from three volunteers showed that there was no difference in the
response of HPBLs that had been collected into heparin or CPD).
HPBLs from each ofthe donors were cultured with DMXAA, FAA
(400jg ml-') or LPS (5 jig ml-'), and TNF activity in the super-
natant was measured after 12 h. Responses to DMXAA above
background were obtained in 11 of the 15 donors with significant
variability between donors. FAA was inactive and in some cases
suppressed background activity. The mean DMXAA response was
1600 ± 680 units per 107cells, while that for LPS was 39 000 ±
5200 units per 107 cells. There was no correlation between the
DMXAA and LPS responses (r = 0.08) or between thebackground
and the DMXAA response (r = 0.47) for this group of donors.
In a further experiment to determine the variability of response
in repeat samples, four samples were taken from each of eight
donors over a period of 3 months. In this experiment, CPD was
used as an anticoagulant and each sample was exposed to
DMXAA (400jig ml-') for 12 h before analysis of TNF activity.
Variability was observed both between individual donors and
between consecutive samples from the same donor, with no
significant difference between individuals except for one, which
produced a consistently negative TNF response (Figure 6).
DISCUSSION
We have shown that DMXAA, in contrast to FAA, can induce TNF
production in cultured HPBLs, thus overcoming the species speci-
ficity that appears to exist for FAA. The results extend previous
observations that TNF mRNA is induced by DMXAA but not by
FAA in the human myeloid HL-60 line (Ching et al, 1994) and that
TNF mRNA is not induced by FAA in HPBLs (Futami et al, 1991).
The lowerconcentration ofDMXAA used forthe in vitro induction
ofTNF mRNA in HPBLs (200,g ml-'; 650 gM) is similar to the in
vivo plasma concentration of DMXAA (600jM) at the maximum
therapeutic dose in mice (McKeage et al, 1991). Moreover, the total
in vitro drug exposure under the optimal conditions (400jg ml
for 2 h; 2600 jimol h 1-') is similar to the area under the plasma
concentration vs time curve (2400 jmol h 1-1) for DMXAA at the
maximum therapeutic dose in mice (McKeage et al, 1991).
After exposure to DMXAA, secreted TNF protein begins to
accumulate in HPBL culture supematants after4 h (Figure 3). The
levels of TNF obtained in response to DMXAA are generally 20-
fold lower than those obtained in cultures of HPBLs stimulated
with LPS (Figures 3 and 6). LPS forms complexes with LPS
binding proteins (LBP) that interact with the CD-14 receptor on
myeloid cells (Haziot et al, 1993). The high sensitivity of the CD-
14 receptor system (Lee et al, 1992) may account for the high
efficiency of LPS in stimulating TNF production. Although the
receptor for DMXAA has not been identified, DMXAA appears to
activate cells by a pathway that is not identical to the one used by
LPS (Perera et al, 1994). The lower amounts and slower kinetics
of TNF production in response to DMXAA, compared with LPS,
suggests differences in the activation pathways of the two agents.
Alternatively, DMXAA and LPS may stimulate different sub-
populations of cells. The cell populations in peripheral blood
responding to DMXAA have not yet been characterized.
A striking observation emerging from these studies is the degree
of inter-individual variation in the TNF response induced with
DMXAA (Figure 4). This heterogeneity is also observed at the
level of mRNA up-regulation (Figure 2), suggesting that the vari-
ability in the levels of TNF protein produced reflect individual
differences in mRNA induction rather than differences in the rates
ofsynthesis or secretion ofthe protein. The response to LPS is also
variable between individuals (Figure 4), consistent with previous
studies (Molvig et al, 1988; Bruin, 1994).
The gene encoding TNF maps within the region encoding the
major histocompatibility gene products on chromosome 6 (Spies et
al, 1986). High TNF production in response to LPS has been shown
to be associated with HLA-DR3, HLA-B8 and HLA-A1 haplotypes
(Jacob et al, 1990) and low TNF production with HLA-DR2 and
DQwl haplotypes (Bendtzen et al, 1988; Jacob et al, 1990), indi-
cating that TNF production in response to LPS is HLA linked.
Several multiallelic polymorphisms within the major histocompati-
bility complex are in very close physical linkage to the TNF locus
(Drouet et al, 1991). In addition, polymorphism in the TNFpromoter
has been described(Manus etal, 1996). Thesepolymorphisms within
the regulatory elements of the TNF gene or in the microsatellite
regions ofthe major histocompatibility complex could be a basis for
the HLA-linked variability in TNF production between individuals.
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It is clear from the present experiments (Figure 4) that indi-
vidual responsiveness of HPBLs to DMXAA and LPS are not
highly correlated, suggesting that the response to DMXAA is not
under the same genetic control from the HLA locus. Apart from
genetic predisposition, inter-individual differences in TNFproduc-
tion can also be caused by hormonal regulation. In humans, LPS
responsiveness in repeated testing is stable in men and post-
menopausal women but fluctuates in premenopausal women,
suggesting regulation by sex hormones (Jacob et al, 1990). We
have shown in mice that the anti-tumour efficacy of DMXAA is
modulated by exogenously administered cortisone, suggesting that
the response to DMXAA may depend on circulating corticos-
teroids (Ching et al, 1993). None ofthe donors used for this study
were on corticosteroid medication, and further work is required to
test the hypothesis that steroid hormones regulate the DMXAA
responsiveness ofHPBLs.
In conclusion, it is pertinent to ask whether the in vitro respon-
siveness ofHPBLs to DMXAAmaybe anindication ofindividual in
vivo responsiveness to DMXAA therapy. Itis known thatthe in vivo
responsiveness of individuals to LPS correlates with the in vitro
ability of their peripheral blood monocytes to secrete TNF in
response to LPS (Bruin, 1994). The demonstration of TNF produc-
tion by HPBLs cultured with DMXAA is ofparticular relevance to
theclinical trials ofDMXAA andraisesthequestion ofwhethersuch
assays should be used in monitoring the course of treatment. The
heterogeneity ofthe responsiveness to DMXAA among individuals,
demonstrated here, emphasizes the need to determine the factors
regulating the response ofpatients selected forDMXAA therapy.
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